ELORAC, Inc. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 15 PAGES: 27

More Info
									      ELORAC, Inc. – Product Pipeline Review – H2 2011

                                                                                          Reference Code: GMDHC01601CDB


                                                                                                 Publication Date: NOV 2011




ELORAC, Inc. – Product Pipeline Review – H2 2011                                            GMDHC01601CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
ELORAC, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 3
      List of Figures .................................................................................................................................................................................................... 3
ELORAC, Inc. Snapshot ........................................................................................................................................................................................... 4
      ELORAC, Inc. Overview ..................................................................................................................................................................................... 4
      Key Information .................................................................................................................................................................................................. 4
      Key Facts ........................................................................................................................................................................................................... 4
ELORAC, Inc. – Research and Development Overview ............................................................................................................................................ 5
      Key Therapeutic Areas ....................................................................................................................................................................................... 5
ELORAC, Inc. – Pipeline Review .............................................................................................................................................................................. 7
      Pipeline Products by Stage of Development ....................................................................................................................................................... 7
      Pipeline Products – Monotherapy ...................................................................................................................................................................... 8
ELORAC, Inc. – Pipeline Products Glance ............................................................................................................................................................... 9
      ELORAC, Inc. – Late Stage Pipeline .................................................................................................................................................................. 9
            Phase III Products/Combination Treatment Modalities ................................................................................................................................. 9
      ELORAC, Inc. Clinical Stage Pipeline Products.................................................................................................................................................10
            Phase II Products/Combination Treatment Modalities .................................................................................................................................10
ELORAC, Inc. – Drug Profiles..................................................................................................................................................................................11
      E-0116 ..............................................................................................................................................................................................................11
            Product Description ....................................................................................................................................................................................11
            Mechanism of Action...................................................................................................................................................................................11
            R&D Progress .............................................................................................................................................................................................11
      E-0301 ..............................................................................................................................................................................................................12
            Product Description ....................................................................................................................................................................................12
            Mechanism of Action...................................................................................................................................................................................12
            R&D Progress .............................................................................................................................................................................................12
      E-0316 ..............................................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action...................................................................................................................................................................................13
            R&D Progress .............................................................................................................................................................................................13
      E-0611 ......................................................................................
								
To top